J. Day

发表

Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.

H. Tutill, J. Day, A. Purohit, 2008, Endocrine-related cancer.

17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer

B. Potter, H. Tutill, B. Potter, 2008 .

STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells

B. Potter, J. Day, A. Purohit, 2008, Clinical Cancer Research.

STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells

B. Potter, J. Day, A. Purohit, 2008, Clinical Cancer Research.

Alternative Splicing in the Aggrecan G3 Domain Influences Binding Interactions with Tenascin-C and Other Extracellular Matrix Proteins*

R. Timpl, Takako Sasaki, T. Hardingham, 2004, Journal of Biological Chemistry.

Effect of topical butyrate on rectal epithelial kinetics and mucosal enzyme activities.

P. Gibson, J. Day, G. Young, 1998, Clinical science.

Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.

H. Tutill, B. Potter, J. Day, 2008, Bioorganic & medicinal chemistry.

Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

H. Tutill, B. Potter, J. Day, 2006, Journal of medicinal chemistry.

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers

B. Potter, J. Day, A. Purohit, 2007, British Journal of Cancer.

The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites

B. Potter, J. Day, A. Purohit, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure

H. Tutill, B. Potter, J. Day, 2009, British Journal of Cancer.

The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells

B. Potter, J. Day, A. Purohit, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer

B. Potter, J. Day, A. Purohit, 2014, British Journal of Cancer.

In vivo and in vitro properties of STX 2484 : a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer

B. Potter, J. Day, A. Purohit, 2014 .

STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.

H. Tutill, B. Potter, J. Day, 2013, Endocrine-related cancer.

Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3

B. Potter, H. Tutill, J. Day, 2009, Molecular and Cellular Endocrinology.

Order within disorder: Aggrecan chondroitin sulphate-attachment region provides new structural insights into protein sequences classified as disordered

T. Jowitt, T. Hardingham, A. Murdoch, 2010, Proteins.

Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol.

A. Romano, K. K. van de Vijver, J. Day, 2012, The Journal of clinical endocrinology and metabolism.

Effects of mutations and glycosylations on STS activity: A site-directed mutagenesis study

H. Tutill, J. Day, A. Purohit, 2008, Molecular and Cellular Endocrinology.

Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3

B. Potter, H. Tutill, J. Day, 2021, Molecules.

The Development of Steroid Sulfatase Inhibitors for Hormone‐Dependent Cancer Therapy

B. Potter, H. Tutill, J. Day, 2009, Annals of the New York Academy of Sciences.

Focused Libraries of 16‐Substituted Estrone Derivatives and Modified E‐Ring Steroids: Inhibitors of 17ß‐Hydroxysteroid Dehydrogenase Type 1

B. Potter, H. Tutill, J. Day, 2006, ChemMedChem.

Cytokines in human breast cyst fluid

J. Day, A. Purohit, M. Reed, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

The Role of 17β-Hydroxysteroid Dehydrogenases in Modulating the Activity of 2-Methoxyestradiol in Breast Cancer Cells

H. Tutill, B. Potter, J. Day, 2006 .

The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells.

H. Tutill, B. Potter, J. Day, 2006, Cancer research.

The regulation and inhibition of 17β-hydroxysteroid dehydrogenase in breast cancer

H. Tutill, J. Day, A. Purohit, 2006, Molecular and Cellular Endocrinology.

The Role of 17 B -Hydroxysteroid Dehydrogenases in Modulating the Activity of 2-Methoxyestradiol in Breast Cancer Cells

H. Tutill, B. Potter, J. Day, 2005 .

17β-Hydroxysteroid dehydrogenase Type 1 and Type 2: Association between mRNA expression and activity in cell lines

B. Potter, H. Tutill, J. Day, 2006, Molecular and Cellular Endocrinology.

The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors

Michael J. Reed, Atul Purohit, H. Tutill, 2009, Molecular and Cellular Endocrinology.

STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice

J. Day, A. Purohit, M. Reed, 2013, PloS one.

STX2171, a 17b-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model

H. Tutill, B. Potter, J. Day, 2013 .